Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aventis To Boost Tetanus Vaccine Production To Meet Needs By Year-End

Executive Summary

Aventis-Pasteur has begun scaling up tetanus vaccine component production and expects to meet U.S. tetanus needs by the end of the year.

You may also be interested in...



DTaP Vaccine Production Is Sufficient For Return To 5-Dose Schedule - CDC

The National Immunization Program estimates that there is sufficient DTaP vaccine in the pipeline to return to the routine five-dose schedule.

DTaP Vaccine Production Is Sufficient For Return To 5-Dose Schedule - CDC

The National Immunization Program estimates that there is sufficient DTaP vaccine in the pipeline to return to the routine five-dose schedule.

Wyeth-Ayerst Acel-Imune Discontinued; DTaP Vaccine Had Sales Of $71 Mil.

Wyeth-Ayerst is discontinuing the DTaP vaccine Acel-Imune, the company said.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037380

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel